[Interstitial pneumonitis in a patient treated with amiodarone -- case report].
Amiodarone, antiarrhythmic drug of III class is used in patients with supraventricular and ventricular arrhythmias, often with coexisting congestive heart failure. Side effects of amiodarone treatment are observed in approximately 75% of patients. Most dangerous are the symptoms of amiodarone pulmonary toxicity occuring in 2-17% of patients. We present a patient with COPD, in whom interstitial pneumonitis with radiologic features of organizing pneumonia developed after one year of amiodaron treatment due to supraventricular and ventricular arrhythmias. The drug was stopped and steroids were introduced due to marked respiratory insufficiency. Regression of pulmonary symptoms and improvement of ventilatory parameters were observed after 3 months of treatment. Pathogenesis, diagnostic procedures and current methods of treatment of this jatrogenic disease are discussed.
Paczek
Anna
A
Klinika Chorob Wewnetrznych Klatki Piersiowej Instytutu Gruzlicy i Chorob Pluc w Warszawie, Poland. 4klinika@igichp.edu.pl
Szturmowicz
Monika
M
Wiatr
Elzbieta
E
Burakowska
Barbara
B
Fijałkowska
Anna
A
Torbicki
Adam
A
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000368:Aged; D000638:Amiodarone / Q000009:adverse effects*; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects*; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000188:drug therapy; D008297:Male; D011014:Pneumonia / Q000139:chemically induced* / Q000188:drug therapy; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy; D012131:Respiratory Insufficiency / Q000139:chemically induced* / Q000188:drug therapy; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D000889:Anti-Arrhythmia Agents; D000638:Amiodarone